| 中文名 | 莱博雷生 |
|---|---|
| 英文名 | (1R,2S)-2-(((2,4-dimethylpyrimidin-5-yl)oxy)methyl)-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl)cyclopropanecarboxamide |
| 中文别名 |
Lemborexant ,莱博雷生
(1R,2S)-2-[[(2,4-二甲基-5-嘧啶基)氧基]甲基]-2-(3-氟苯基)-N-(5-氟-2-吡啶基)环丙烷甲酰胺(莱博雷生) 博雷生 莱博雷声 莱博雷生杂质1 (1R,2S)-2-[[(2,4-二甲基-5-嘧啶基)氧基]甲基]-2-(3-氟苯基)-N-(5-氟-2-吡啶基)环丙烷甲酰胺 (1R,2S)-2-((2,4-二甲基嘧啶-5-基)氧)甲基)-2-(3-氟苯基)-N-(5-氟吡啶-2-基)环丙烷-1-甲酰胺 伦波克桑 |
| 英文别名 |
Lemborexant API
Lemborexan (1S,2R)-2-(((2,4-dimethylpyrimidin-5-yl)oxy)methyl)-1-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl)cyclopropanecboxamide E-2006; E 2006; E2006; LEMBOREXANT; DAYVIGO Lemborexant //BP Cyclopropanecboxamide, 2-[[(2,4-dimethyl-5-pyrimidinyl)oxy]methyl]-2-(3-fluorophenyl)-N-(5-fluoro-2-pyridinyl)-, (1R,2S) (1R,2S)-2-{[(2,4-dimethylpyrimidin-5-yl)oxy]methyl}-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl)cyclopropanecarboxamide labradon Lemborexant Impurity 1 (1R,2S)-2-[[(2,4-Dimethyl-5-pyrimidinyl)oxy]methyl]-2-(3-fluorophenyl)-N-(5-fluoro-2-pyridinyl)cyclopropanecboxamide (1R,2S)-2-[(2,4-DIMETHYLPYRIMIDIN-5-YL)OXYMETHYL]-2-(3-FLUOROPHENYL)-N-(5-FLUOROPYRIDIN-2-YL)CYCLOPROPANE-1-CBOXAMIDE lemborexant,E2006 Dayvigo (1R,2S)-2-[[(2,4-dimethyl-5-pyrimidine)oxy]methyl]-2-(3-fluorophenyl)-N-(5-fluoro-2-pyridyl)cyclopropaneformamide (Leborethen) E-2006 Lemborexant Lemborexant (1R,2S)-2-{[(2,4-Dimethyl-5-pyrimidinyl)oxy]methyl}-2-(3-fluorophenyl)-N-(5-fluoro-2-pyridinyl)cyclopropanecarboxamide lemborexant / E-2006, CID 2-((1S,2S)-2-(((2,4-dimethylpyrimidin-5-yl)oxy)methyl)-2-(3-fluorophenyl)cyclopropyl)-N-(5-fluoropyridin-2-yl)acetamide |
| 描述 | Lemborexant (E-2006)是食欲素受体OX1和OX2双重抑制剂,临床2期由于治疗失眠。 |
|---|---|
| 相关类别 |
| 密度 | 1.3±0.1 g/cm3 |
|---|---|
| 沸点 | 596.1±50.0 °C at 760 mmHg |
| 分子式 | C22H20F2N4O2 |
| 分子量 | 410.417 |
| 闪点 | 314.3±30.1 °C |
| 精确质量 | 410.155426 |
| PSA | 77.00000 |
| LogP | 3.16 |
| 蒸汽压 | 0.0±1.7 mmHg at 25°C |
| 折射率 | 1.619 |
| 储存条件 | 2-8℃ |